CoQ10 and wrinkles around the eyes
Study result for water-soluble Q10Vital and measured wrinkle area.
Key points
- In healthy women aged 45–60, water-soluble Q10Vital reduced the measured area of wrinkles around the eyes compared with placebo over 12 weeks. For this product and duration there is a preliminary signal of a possible reduction in wrinkle area around the eyes. [1] See the evidence 1
- The study used the specific water-soluble product Q10Vital, and CoQ10 forms in supplements differ. When comparing products, check the composition and form of each specific product. [1] [2] See the evidence 1 2
Practical guide
Check the conclusions and whether they apply to your situation.
The study assessed a specific product and an appearance measure.
Key points
Why these conclusions
The Q10Vital study
Healthy women aged 45–60 received water-soluble CoQ10 Q10Vital in syrup at 50 or 150 mg daily or placebo syrup for 12 weeks. Measured wrinkle area around the eyes decreased compared with placebo; certainty is very low. [1]
Ubiquinone and ubiquinol are different CoQ10 forms; interconversion does not mean that products are interchangeable. [2]
In a small study, concentrations after 100 mg of ubiquinone with cyclodextrin and standard ubiquinone were compared in 21 participants; the difference in blood concentrations does not prove clinical superiority of either formulation. [3]
In women aged 45–60, water-soluble Q10Vital reduced the measured area of wrinkles around the eyes compared with placebo over 12 weeks.
| Parameter | Data |
|---|---|
| Result | In women aged 45–60, water-soluble Q10Vital reduced the measured area of wrinkles around the eyes compared with placebo over 12 weeks. p=0.04 for each dose versus placebo. |
| Participants | 33 healthy women aged 45–60, three groups of 11 |
| Form | Water-soluble CoQ10 Q10Vital orally in syrup |
| Dose | 50 or 150 mg/day |
| Dose basis | 50 or 150 mg/day |
| Comparator | Placebo syrup |
| Duration | 12 weeks |
| Confidence | 1/4: Precision: Small samples, intervals and uncertain clinical significance. Consistency: Insufficient data for a separate downgrade. Applicability to the specified group: The stated form, outcome, clinical context and population limit transferability. Possible publication bias: Insufficient data for a separate downgrade. Study methods: Limitations in assessing design, reporting or losses. |
| Evidence base | 1 trial; outcome from the same participant group |
| Sources | [1] |
Ubiquinone and ubiquinol are different CoQ10 forms; interconversion does not mean that products are interchangeable.
Ubiquinone and ubiquinol are different CoQ10 forms; interconversion does not mean that products are interchangeable. [2]
In a small study, concentrations after 100 mg of ubiquinone with cyclodextrin and standard ubiquinone were compared in 21 participants; the difference in blood concentrations does not prove clinical superiority of either formulation.
In a small study, concentrations after 100 mg of ubiquinone with cyclodextrin and standard ubiquinone were compared in 21 participants; the difference in blood concentrations does not prove clinical superiority of either formulation. [3]
Sources
- The effect of dietary intake of coenzyme Q10 on skin parameters and condition: Results of a randomised, placebo-controlled, double-blind study. https://pubmed.ncbi.nlm.nih.gov/27548886/
- FDA UNII registry record: UBIDECARENONE (UNII EJ27X76M46). https://precision.fda.gov/ginas/app/ui/substances/EJ27X76M46
- Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals. https://pmc.ncbi.nlm.nih.gov/articles/PMC7146408/
Methodology: Subpages evidence-led supplement pipeline v1